key: cord-0864206-tr2e8kbm
authors: Qu, Wenchun; Wang, Zhen; Hare, Joshua M.; Bu, Guojun; Mallea, Jorge M.; Pascual, Jorge M.; Caplan, Arnold I.; Kurtzberg, Joanne; Zubair, Abba C.; Kubrova, Eva; Engelberg‐Cook, Erica; Nayfeh, Tarek; Shah, Vishal P.; Hill, James C.; Wolf, Michael E.; Prokop, Larry J.; Murad, M. Hassan; Sanfilippo, Fred P.
title: Cell‐based therapy to reduce mortality from COVID‐19: Systematic review and meta‐analysis of human studies on acute respiratory distress syndrome
date: 2020-05-29
journal: Stem Cells Transl Med
DOI: 10.1002/sctm.20-0146
sha: 3d5c0e6934d2689502fc3206fb734507a34d115b
doc_id: 864206
cord_uid: tr2e8kbm

Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers. The authors performed a systematic literature review and random‐effects meta‐analysis to determine the potential value of MSC therapy for treating COVID‐19‐infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO(2)/FiO(2) ratio, alveolo‐capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.

As a common enveloped RNA virus that crosses species, 1 COVID-19 has been associated with an intensive care unit (ICU) admission rate of 5% of proven infections 3 and an overall mortality rate in the range of 0.5% to 7%. 4 Among patients who require hospitalization, mortality may be approximately 5% to 15%. 3, 5 Current treatment for patients with acute lung injuries is supportive, but with a high case fatality rate of 22% to as high as 88% for ICU patients. 3, 5, 6 Importantly, age represents a major risk factor for mortality. 6 New treatment modalities are needed to save lives by addressing the underlying pathophysiological processes that prevent oxygen exchange and destruction of the alveoli.

Similar to prior findings in SARS and MERS, COVID-19/SARS-CoV-2 in severe cases leads to fatal acute respiratory distress syndrome (ARDS), associated with monocyte and macrophage infiltration, diffuse alveolar damage, and cellular fibromyxoid exudates 7, 8 with mortality reported as high as 52.4%. 4 The respiratory distress peaks at 7 to 10 days with manifestations of immune dysregulation, including cytokine release syndrome with elevation of cytokine levels (IL-6, IL-8, IL-1, IL2R, IL-10, and TNF-α), lymphopenia (in CD4+ and CD8+ T cells), and decreases in IFN-γ expression in CD4+ T cells. 8, 9 The inverse correlation between cytokine storm with lower CD4+ and CD8+ counts suggests that the cytokine response may dampen adaptive immunity against COVID-19 infection, 10 which is associated with atrophy of the secondary lymphoid tissues. 7 Anti-inflammatory treatment has been proposed but challenged with the dilemma of balancing the risk of secondary infection. 11 Mesenchymal stromal cells (MSCs, also known as mesenchymal stem 12 MSCs have been studied as a promising candidate to treat certain inflammatory conditions and immunologic diseases based upon their well-characterized immunomodulatory effects, especially in the treatment of graft-vs-host disease, where MSC therapy was found to substantially improve complete response and overall survival. 13, 14 The immunomodulatory activities are thought to include (a) inhibition of the proliferation and function of T cells, B cells, dendritic cells, and natural killer cells; (b) monocyte polarization to anti-inflammatory M2 macrophages; and (c) production of IL-10 and decreased production of TNF-α and IL-12. [15] [16] [17] In addition, MSCs have powerful antifibrotic effects and may alleviate lung fibrosis. 18, 19 An urgent question is whether large-scale clinical trials and compassionate use of MSC therapy should be instituted to treat COVID-19-induced ARDS. To address this question, we systematically reviewed the available literature on safety, efficacy, and cytokine responses to MSC therapies in patients with ARDS.

The study protocol was finalized at the beginning of the project, which defined objectives, search strategy, inclusion/exclusion criteria, data extraction, outcomes of interest, and analytical approaches.

The potential benefits of mesenchymal stromal cell (MSC) 

We included randomized controlled trials (RCTs), observational studies, case reports, and case series that evaluated safety and/or efficacy of stem cells administered to adult patients with a diagnosis of COVID-19 pneumonia or ARDS from any cause. MSCs that were culture-expanded or minimally manipulated were included. We included studies regardless of language of publication. Studies were excluded if they did not report original data (eg, clinical reviews, editorials, letters, or erratum).

The primary outcome was safety based on the frequency of serious adverse events (SAEs), adverse events (AEs), and if they were related to the treatment with MSCs.

Other outcomes of interest were clinical and laboratory findings, including mortality, level of oxygenation, lymphopenia, PaO 2 / FiO 2 ratio, FEV1, FVC, FEV1/FVC, FEF50%, ventilator-free days, ICU-free days, organ failure-free days, inflammatory markers including IL-1, IL-6, IL-8, RAGE, TNF-α, and CRP, angiotensin II, IL-10.

Radiographic and computed tomographic (CT) findings were also included. were resolved by a third independent reviewer (W. Q.) ( Figure 1 ).

A standardized data extraction form was developed and piloted.

We extracted publication characteristics, study population, intervention and comparison details, and outcomes measures.

For RCTs, we used the Cochrane risk of bias tool to evaluate bias from sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessor, incomplete outcome data, selective outcome reporting, and other sources of bias. For observational studies, case series, and case reports, we used the Newcastle-Ottawa

Scale to evaluate representativeness of study population, ascertainment of exposure, comparability between groups (if applicable), outcome data source, and blinding of outcome assessment (Appendix 1, Tables 1 and 2) . We used the GRADE approach (Grading of recommendations, development assessment and Evaluation) to rate certainty in the effect of MSC on mortality. 29 

We conducted meta-analysis to quantitatively summarize study findings based on the similarities of PICOTS (patient, intervention, control, outcome, timing, setting) presented by the studies. Mortality was the only outcome deemed to be appropriate for meta-analysis. included for the data extraction. Full text exclusion reasons are presented in Table 3 .

Of the nine studies, there were four phase I clinical trials, three phase I/II or phase II clinical trials, one case report, and one case series. Five were comparative studies with control groups, including three RCTs.

All nine studies reported SAEs, AEs, mortality, and pulmonary function outcomes (n = 200). Six studies evaluated inflammatory markers (n = 98). A total of 117 patients received MSC therapy, while 83 participated as controls ( Table 1 ). The risk of bias of included randomized trials was high due to unclear random sequence generation and allocation concealment procedures.

The studies were from six countries and regions, including China (n = 3), 20, 22, 26 the United States (n = 2), 21, 24 United States/United Kingdom (n = 1), 23 Sweden (n = 1), 28 Taiwan (n = 1), 25 and South Korea (n = 1). 27 The average age of study participants was 51 to 67 years for the MSC groups and 55 to 70 years for the control groups in the comparative studies. Baseline PaO 2 /FiO 2 was in a range of 100 to 200 in six studies [21] [22] [23] [24] [25] 27 and not reported in two studies in which all patients were on ventilator or extracorporeal membrane oxygenation (ECMO) support. 26, 28 Baseline Acute Physiology and Chronic Health Evaluation (APACHE) scores were between 23 and 27 in one study, 22 averaged 108 in one study, 21 and 104 in the MSC group vs 89 in the control group in one study 24 (Table 1 ). MSCs in one study, 25 and umbilical cord blood MSCs in one study. 27 One study did not report the tissue origin of the MSCs and described their cell-product as commercially obtained 20 ( 

Mild AEs were reported. One patient experienced a grade I allergic reaction. 23 In another study, patients experienced diarrhea in both treatment groups. 22 scores. 24 The overall mortality rates were 25% (24 of 96) for MSCtreated patients and 43% (36 of 83) in controls. Although there was a favorable trend, the overall difference did not reach statistical significance (Peto OR 0.63, 95% confidence interval 0.21-1.93). The certainty in evidence about an effect on mortality was low, due to imprecision and methodological limitations of the included trials, as presented in Figure 2 and Table 5 .

All studies reported pulmonary function tests as outcome mea- 

Systemic changes were reported as any changes to overall patient status, including mental status, SOFA score, quality of life (SF-36), laboratory markers of organ function, symptoms, and relative improvements from baseline (Table 5) . 20-22,24-28

Inflammatory markers and cytokines were evaluated in six studies.

These showed clear decreases in pro-inflammatory cytokines, including IL-1, IL-6, TNF-α, and CRP, and increased lymphocytes and IL-10 within 5 days of MSC therapy ( Findings from this study also suggest the impact of MSC therapy on important immunologic and inflammatory processes that lead to organ injury in COVID-19-infected patients. Cytokine release syndrome is a major underlying pathophysiological process in ARDS and was found to decrease with MSC therapy in seven of the studies analyzed. [20] [21] [22] [23] [24] [25] 28 In addition, MSCs have been hypothesized to neutralize free virus particles through the production of antibiotic proteins like LL37, which bind to virus and lung cell binding sites. 42 As recently reported, COVID-19 not only affects the lung, but also the heart and kidney with reported cardiomyopathy and kidney injury. 43, 44 Two of the analyzed studies reported improved resolution of multiple organ failure or increased organ failure-free days with MSC treatment, which further supports their consideration for clinical use. Future clinical trials should include multiorgan failure parameters.

Senior age is associated with higher rate of mortality and has been reported to be associated with higher risk of death in patients with COVID-19. 45, 46 In comparative studies included in this review, the age ranges were similar in both the MSC and the control groups at baseline and appeared to have minimal impact on outcomes. 

The limitations of this systematic review include the lack of large-scale 

Data sharing is not applicable to this article as no new data were created or analyzed in this study. 

Evidence supporting a zoonotic origin of human coronavirus strain NL63

Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Care for critically ill patients with COVID-19

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical and immunologic features in severe and moderate coronavirus disease 2019

SARS-CoV-2: a storm is raging

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

Five generations of cell preparation: a translational framework for categorizing regenerative stem cell therapies

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine

Mesenchymal stem cell perspective: cell biology to clinical progress

Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells

Human mesenchymal stein cells alleviate bleomycininduced pulmonary fibrosis in humanized mice

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

Transplantation of ACE2 − mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Primary analysis of a phase 1/2 study to assess MultiStem® cell therapy, a regenerative advanced therapy medicinal product (ATMP), in acute respiratory distress syndrome (MUST-ARDS)

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza a (H7N9) infection, a hint for COVID-19 treatment. Engineering

Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome

In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome

Clinical practice guidelines: a primer on development and dissemination

Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies

Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS

CELLTOP clinical trial: first report from a phase 1 trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial

Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial

Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease

Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease

Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula

Early results of a phase I trial using an adipose-derived mesenchymal stem cell-coated fistula plug for the treatment of transsphincteric cryptoglandular fistulas

Feasibility, safety, and tolerance of mesenchymal stem cell therapy for obstructive chronic lung allograft dysfunction

Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Caution on Kidney Dysfunctions of COVID-19 Patients

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC weekly, vital surveillances

Pluristem Expands Its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program

Pluristem Reports Preliminary Data from Its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure

Cellbased therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome

ACTUAL SEARCH STRATEGY Ovid Database(s): EBM Reviews-Cochrane Central Register of Controlled Trials

Corona virinae" or "corona virus" or Coronavirinae or coronavirus or COVID or nCoV or HCoV

Corona virinae" or "corona virus" or Coronavirinae or coronavirus or COVID or nCoV or HCoV) and Wuhan) OR "Acute Respiratory Distress Syndrome" OR ARDS OR "Corona virinae19" OR "Corona virinae2019" OR "corona virus19" OR "corona virus2019" OR Coronavirinae19 OR Coronavirinae2019 OR coronavirus19 OR coronavirus2019 OR COVID19 OR COVID2019 OR "cytokine storm*" OR "interstitial pneumonia*" OR MERS OR "Middle East Respiratory Syndrome" OR nCOV19 OR nCOV2019 OR "SARS Corona virus" OR

OR "adipose stromal stem cell*" OR "bone marrow derived stromal cell*" OR "bone marrow derived stromal stem cell*" OR "bone marrow stromal cell*" OR "bone marrow stromal stem cell*" OR "colony forming unit*" OR "mesenchymal cell*" OR "mesenchymal progenitor cell*" OR "mesenchymal stem cell*" OR "mesenchymal stromal cell*" OR "mother cell*" OR MSC OR MSCs OR "progenitor cell*" OR "stem cell*" OR "umbilical cord derived stromal cell*" OR "umbilical cord derived stromal stem cell*" OR "umbilical cord stromal cell*" OR "umbilical cord stromal stem cell

INDEX(embase) OR INDEX(medline) OR

2019 novel coronavirus" OR "2019-nCoV" OR "acute respiratory distress" OR "acute respiratory syndrome" OR ARDS OR Coronavirus OR "COVID 19" OR "cytokine storm" OR "interstitial pneumonia" OR MERS OR "Middle East Respiratory Syndrome" OR "SARS-CoV") ("viral pneumonia" OR "virus pneumonia

progenitor cell" OR "stem cell" OR "stromal cell" OR "wharton jelly cell" OR "whartons jelly cell") First posting